As the founder of Seattle Genetics, Inc., Clay Siegall, Ph.D., created a dynamic company which develops targeted drug therapies that treat diseases. His focus as Chief Executive Officer is to research drugs that can offer new therapies for diseases that haven’t seen any meaningful survival rate improvement in decades.
Dr. Clay Siegall’s excellent leadership of the company and focus on research and development of antibody-drug conjugates has led Seattle Genetics to be one of the leaders in the biotechnology industry. He successfully introduced one drug so far onto the market that targets lymphoma without harming nearby non-cancerous cells like most drug therapies do. This drug also shows a great deal of promise in curing other forms of cancer so it is being researched further. He has more than 20 other drugs in the pipeline that he is developing through partnerships he has formed with industry giants such as Genentech, Bayer, and Pfizer.
Dr. Siegall started Seattle Genetics with a small crew of dedicated researchers. It is now a large team of medical professionals who are on the cutting edge of science in the field of cancer drugs. Early on, Dr. Clay Siegall recognized that the old way of treating cancer was too ineffective and harmful. Targeted drug therapies, like what he develops, leave healthy tissue and blood alone while solely targeting cancerous cells. He believes this is the wave of the future and will completely upend the conventional way of treating cancer.
It was while Dr. Siegall was attending the University of Maryland, earning a degree in zoology, that he first became interested in cancer research. This was due to his father developing cancer and him witnessing first hand how brutal the treatment was. His father almost died but it was due to the chemotherapy he was being treated with rather than cancer itself that was the cause. He went on to attend George Washington University where he earned his Ph.D. in Genetics so that he would have the educational background necessary to change this state of affairs. He has dedicated himself to helping people beat cancer and improving peoples lives.
In the recent past, Rutgers Cancer Institute devised the Omar Boraie Chair in Genomic Science. The endowed chairs shall pledge their commitment towards an academic discipline. Omar Boraie was the first to be named as the chair. He made his commitment of $1.5 million to the endowment fund. The Omar Boraie Chair is part of the institution’s ’18 Chair Challenge’ campaign, http://patch.com/new-jersey/newbrunswick/omar-boraie-chair-genomic-science-established-rutgers-cancer-institute. According to the plan, an anonymous donor will commit $1.5 million to match all the 18 chairs. In total, each chairs will raise $3 million.
Genomic science and precision medicine has played a crucial role in changing the procedure of diagnosing and treating cancer. The relatively new field focuses on examining and treating tumors and permitting oncologists to recommend therapies based on individual needs. In his State of Union Address, President Obama launched a noble precision medicine initiative aimed at developing treatment that can cure cancer and other illnesses. Rutgers Cancer Institute was among the pioneers in the state and nation to apply genomic sequencing as an innovative strategy of curing cancer through precision medicine.
Genomic sequencing has played a pivotal role in the development of novel therapies for individuals having poorer prognosis, rare cancer and those experiencing ineffective or limited treatment options. Advancements in precision medicine will make it possible for medical practitioners to classify cancer into sub-populations having the same features but dissimilar genetics. This strategy will enhance better prediction of patient outcome and determine appropriate cancer therapies that address an individual’s need.
At Rutgers Cancer Institute, Physician-scientists have made strides with precision medicine, especially for patients having unresponsive cancers. Omar Boraie posited that his support and that of many others would make it possible for the institution to develop effective cancer therapies that would benefit all cancer patients. Omar has a degree in chemistry. Over the years, he has been interested in cancer research. Boraie was hopeful that his contribution as the ‘18 Chair Challenge‘s’ anonymous donor would inspire many people to donate towards the noble cause.
For many years, Boraie has played an instrumental role in developing New Brunswick to serve as a healthcare hub. Robert DiPaola, MD, the director of Rutgers Cancer Institute posited that Omar’s involvement in genomic science would have a permanent impact on the diagnosis and treatment of cancer beyond New Brunswick. This information was originally published on NewsWise as outlined in this link http://newswise.com/articles/omar-boraie-chair-in-genomic-science-established-at-rutgers-cancer-institute
The principal investigator in charge of clinical trials and precision medicine at the institution, Shridar Ganesan, MD, PhD, posited that they have learnt that cancer is a collection of different diseases. He was honored to make it to the list of the Omar Boraie Chair in Genomic Science. Ganesan remains optimistic that that the funding will renew the hopes of many cancer patients.